H. Lee Moffitt Cancer Center & Research Institute Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:H. Lee Moffitt Cancer Center & Research Institute Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5161
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider. It is engaged in the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services such as surgical care, fertility preservation, radiation therapy, interventional radiology, rehabilitation services, chemotherapy, cardio-oncology, blood and bone marrow transplant, cancer survivorship clinic, tumor board, interventional pain management, supportive care medicine, survivorship program, clinical trials, and others. It treats various types of cancers such as anal cancer, bladder cancer, brain cancer, breast cancer, colorectal cancer, esophageal cancer, gallbladder cancer and gastrointestinal carcinoid tumor, among others. Moffitt is headquartered in Tampa, Florida, the US.

H. Lee Moffitt Cancer Center & Research Institute Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
H. Lee Moffitt Cancer Center & Research Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
MultiVir Enters into Licensing Agreement with Moffitt Cancer Center 13
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 14
Certainty Therapeutics Enters into Agreement with Moffitt Cancer Center 15
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 16
Vycellix Enters into Research Agreement with Moffitt Cancer Center 17
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Morphogenesis Enters into Agreement with Moffitt Cancer Center 20
Ignyta Enters into Research Agreement with Moffitt Cancer Center 21
HealthMyne Enters into Research Agreement with Moffitt Cancer Center 22
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 23
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 24
Moffitt Cancer Center Enters Into Agreement With Advinus For Target Cancer Therapies 25
Moffitt Cancer Center, Sanford-Burnham Medical Research Institute And Florida Hospital Enter Into Partnership To Form Personalized Medicine Partnership of Florida 26
Licensing Agreements 28
Moffitt Cancer Center Enters into Licensing Agreement with Lixte Biotechnology 28
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 29
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 30
Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 31
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 32
H. Lee Moffitt Cancer Center & Research Institute Inc – Key Competitors 34
H. Lee Moffitt Cancer Center & Research Institute Inc – Key Employees 35
H. Lee Moffitt Cancer Center & Research Institute Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Government and Public Interest 38
Jul 18, 2018: New studies show daily Aspirin use reduces ovarian cancer risk and improves survival after diagnosis 38
Jul 09, 2018: Moffitt Cancer Center Researcher Receives $200,000 Grant to Investigate Pancreatic Cancer 40
Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 41
Mar 27, 2018: Screening High-Risk Individuals Can Reduce Multiple Myeloma Mortality 42
Mar 13, 2018: Moffitt researchers use single-cell imaging & math models to find effect drug properties 43
Mar 13, 2018: Moffitt Researchers Use Single-Cell Imaging and Mathematical Modeling to Determine Effective Drug Properties 44
Jun 12, 2017: Moffitt researchers identify inhibitor that overcomes drug resistance in prostate cancer 45
Jan 11, 2017: Moffitt researchers develop novel treatment to prevent graft-versus-host-disease 46
Product News 47
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 47
Other Significant Developments 49
Aug 17, 2018: Moffitt Cancer Center and ITUS announce scheduling of Pre-IND Meeting with the FDA for their CAR-T therapy 49
Mar 27, 2018: Moffitt Is Only Cancer Center In Florida Named 2018 LGBTQ Healthcare Equality Leader 50
Jan 18, 2018: Lung Cancer Patients to Help Medical Community Understand the Side Effects of Immunotherapy Treatment 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Key Facts 2
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
H. Lee Moffitt Cancer Center & Research Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 9
H. Lee Moffitt Cancer Center & Research Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MultiVir Enters into Licensing Agreement with Moffitt Cancer Center 13
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 14
Certainty Therapeutics Enters into Agreement with Moffitt Cancer Center 15
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 16
Vycellix Enters into Research Agreement with Moffitt Cancer Center 17
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Morphogenesis Enters into Agreement with Moffitt Cancer Center 20
Ignyta Enters into Research Agreement with Moffitt Cancer Center 21
HealthMyne Enters into Research Agreement with Moffitt Cancer Center 22
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 23
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 24
Moffitt Cancer Center Enters Into Agreement With Advinus For Target Cancer Therapies 25
Moffitt Cancer Center, Sanford-Burnham Medical Research Institute And Florida Hospital Enter Into Partnership To Form Personalized Medicine Partnership of Florida 26
Moffitt Cancer Center Enters into Licensing Agreement with Lixte Biotechnology 28
Moffitt Cancer Center Enters into Licensing Agreement with Celgene 29
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 30
Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 31
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 32
H. Lee Moffitt Cancer Center & Research Institute Inc, Key Competitors 34
H. Lee Moffitt Cancer Center & Research Institute Inc, Key Employees 35
H. Lee Moffitt Cancer Center & Research Institute Inc, Subsidiaries 37

List of Figures
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
H. Lee Moffitt Cancer Center & Research Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
H. Lee Moffitt Cancer Center & Research Institute Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[H. Lee Moffitt Cancer Center & Research Institute Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GlycoMimetics Inc (GLYC):製薬・医療:M&Aディール及び事業提携情報
    Summary GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company’s products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis o …
  • DexTech Medical AB:製薬・医療:M&Aディール及び事業提携情報
    Summary DexTech Medical AB (DexTech) is a research company that conducts research in the areas of urological oncology, mainly within prostate cancer. The company develops product candidates based on a modified carbon hydrate molecule combined with active substances such as generics. Its technology p …
  • Taiwan High Speed Rail Corporation:企業の戦略・SWOT・財務情報
    Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report Summary Taiwan High Speed Rail Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Turcas Petrol AS (TRCAS):企業の財務・戦略的SWOT分析
    Summary Turcas Petrol AS (Turcas) is an oil and gas company that distributes and markets lubricants and fuel products. The company operates in the fields of oil and energy, renewable energy, power investments, natural gas projects, fuel retail and lubricants distribution, and power generation and tr …
  • Cytox Ltd-医療機器分野:企業M&A・提携分析
    Summary Cytox Ltd (Cytox) is a diagnostic and prognostic service provider that develops services for neurodegenerative disorders. The company’s blood tests are used to predict, which patients with MCI will develop Alzheimer's disease. Its biomarkers are based on the cell cycle hypothesis of Alzheime …
  • EnCana Corporation:戦略・SWOT・企業財務分析
    EnCana Corporation - Strategy, SWOT and Corporate Finance Report Summary EnCana Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PetroNeft Resources plc (P8ET):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroNeft Resources Plc (PetroNeft) is an upstream oil and gas company. It carries out exploration, development and production of oil and natural gas. The company mainly focuses on oil rich Western Siberia zone in Russia. PetroNeft’s asset base comprises of 50% interest each in License 61 an …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • iPass Inc.:企業の戦略的SWOT分析
    iPass Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • HCP Inc (HCP):企業の財務・戦略的SWOT分析
    HCP Inc (HCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • The Export-Import Bank of Korea:電力:M&Aディール及び事業提携情報
    Summary The Export-Import Bank of Korea (Korea Eximbank) is a bank that offers financial products and services. The company’s products include loans, guarantees, bonds, trade finance products, investment products, and structured products. Its loan products comprise export related loans, overseas bus …
  • Nigerian National Petroleum Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Nigerian National Petroleum Corp (NNPC) is a state-owned vertically integrated oil and gas company, which explores for, produces, markets and distributes crude oil, refined petroleum, petrochemicals and associated by-products. It operates through a network of refineries that produce products …
  • bioMerieux Inc-医療機器分野:企業M&A・提携分析
    Summary bioMerieux Inc (bioMerieux), a subsidiary of Institut Merieux SA is a provider of diagnostic solutions. The company offers its products for clinical solutions which include blood culture, cancer diagnostics, cardiovascular disease, cardiovascular pathology, clinical laboratories, companion d …
  • EchoStar Corporation:企業の戦略・SWOT・財務情報
    EchoStar Corporation - Strategy, SWOT and Corporate Finance Report Summary EchoStar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Antitope Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibo …
  • Stemline Therapeutics Inc (STML):製薬・医療:M&Aディール及び事業提携情報
    Summary Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pi …
  • Clicks Group Limited:企業の戦略・SWOT・財務分析
    Clicks Group Limited - Strategy, SWOT and Corporate Finance Report Summary Clicks Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fujita Kanko Inc:企業の戦略・SWOT・財務情報
    Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report Summary Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • WESCO International, Inc.:企業の戦略・SWOT・財務分析
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CIRCOR International, Inc. (CIR):石油・ガス:M&Aディール及び事業提携情報
    Summary CIRCOR International Inc (CIRCOR) is an industrial equipment company that designs, manufactures, and markets flow control solutions and engineered products and sub-systems. Its product offerings include integrated flow control solutions, high pressure pneumatic systems, valves, actuation, sw …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆